(EMSN) EMS-CHEMIE HOLDING - Ratings and Ratios
Polyamide Granulate, Specialty Chemicals, Adhesives, Fibers, Coatings
Description: EMSN EMS-CHEMIE HOLDING
EMS-CHEMIE HOLDING AG is a leading global supplier of high-performance polymers and specialty chemicals, serving various industries such as automotive, electronics, and consumer goods. The companys product portfolio includes high-performance polyamide granulate, fibers, adhesives, and coating systems, which are used in a wide range of technical and textile applications.
The companys High Performance Polymers segment is a key driver of growth, with a strong focus on innovation and customer-specific solutions. The Specialty Chemicals segment also contributes significantly to the companys revenue, with a diverse range of products used in various industries. EMS-CHEMIE HOLDING AGs global presence, with operations in the US, Europe, and Asia, enables it to effectively serve its customers worldwide.
From a financial perspective, EMS-CHEMIE HOLDING AG has demonstrated strong profitability, with a Return on Equity (RoE) of 48.30%. The companys market capitalization stands at approximately 14.9 billion CHF, indicating its significant size and market presence. The stocks Price-to-Earnings (P/E) ratio is around 31.81, which may be considered relatively high, suggesting that investors have high expectations for the companys future growth.
To further evaluate the companys performance, some key performance indicators (KPIs) to consider include: Revenue Growth Rate, Gross Margin, Operating Margin, and Debt-to-Equity Ratio. Analyzing these KPIs can provide insights into the companys ability to generate revenue, maintain profitability, and manage its debt obligations. Additionally, metrics such as Dividend Yield and Payout Ratio can be useful for income investors.
Overall, EMS-CHEMIE HOLDING AGs strong market position, diverse product portfolio, and global presence make it an attractive investment opportunity for investors seeking exposure to the specialty chemicals sector. However, a thorough analysis of the companys financials and KPIs is necessary to determine its investment potential.
EMSN Stock Overview
| Market Cap in USD | 18,058m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
EMSN Stock Ratings
| Growth Rating | -41.3% |
| Fundamental | 78.1% |
| Dividend Rating | 24.7% |
| Return 12m vs S&P 500 | -25.1% |
| Analyst Rating | - |
EMSN Dividends
| Dividend Yield 12m | 2.26% |
| Yield on Cost 5y | 1.89% |
| Annual Growth 5y | -3.95% |
| Payout Consistency | 94.0% |
| Payout Ratio | 1.5% |
EMSN Growth Ratios
| Growth Correlation 3m | 69.5% |
| Growth Correlation 12m | -55% |
| Growth Correlation 5y | -71% |
| CAGR 5y | -3.65% |
| CAGR/Max DD 5y | -0.08 |
| Sharpe Ratio 12m | -1.24 |
| Alpha | -18.94 |
| Beta | 0.310 |
| Volatility | 19.04% |
| Current Volume | 9.3k |
| Average Volume 20d | 10.6k |
| Stop Loss | 595 (-3%) |
| Signal | -1.76 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (918.4m TTM) > 0 and > 6% of Revenue (6% = 255.6m TTM) |
| FCFTA 0.46 (>2.0%) and ΔFCFTA 11.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 28.60% (prev 57.86%; Δ -29.27pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.50 (>3.0%) and CFO 1.11b > Net Income 918.4m (YES >=105%, WARN >=100%) |
| Net Debt (-509.6m) to EBITDA (1.15b) ratio: -0.45 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (23.4m) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin 45.38% (prev 39.21%; Δ 6.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 193.9% (prev 112.7%; Δ 81.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 266.9 (EBITDA TTM 1.15b / Interest Expense TTM 3.91m) >= 6 (WARN >= 3) |
Altman Z'' 15.53
| (A) 0.55 = (Total Current Assets 1.46b - Total Current Liabilities 240.8m) / Total Assets 2.23b |
| (B) 0.90 = Retained Earnings (Balance) 2.01b / Total Assets 2.23b |
| warn (B) unusual magnitude: 0.90 — check mapping/units |
| (C) 0.47 = EBIT TTM 1.04b / Avg Total Assets 2.20b |
| (D) 5.54 = Book Value of Equity 2.01b / Total Liabilities 362.5m |
| Total Rating: 15.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.11
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 7.39% = 3.69 |
| 3. FCF Margin 24.21% = 6.05 |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda 0.00 = 2.50 |
| 6. ROIC - WACC 39.27% = 12.50 |
| 7. RoE 48.30% = 2.50 |
| 8. Rev. Trend -56.22% = -2.81 |
| 9. Rev. CAGR -5.98% = -1.00 |
| 10. EPS Trend -13.18% = -0.33 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of EMSN shares?
Over the past week, the price has changed by -1.68%, over one month by -3.87%, over three months by +0.36% and over the past year by -12.40%.
Is EMS-CHEMIE HOLDING a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EMSN is around 549.94 CHF . This means that EMSN is currently overvalued and has a potential downside of -10.36%.
Is EMSN a buy, sell or hold?
What are the forecasts/targets for the EMSN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 660.7 | 7.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 605.8 | -1.3% |
EMSN Fundamental Data Overview
Market Cap CHF = 14.48b (14.48b CHF * 1.0 CHF.CHF)
CCE Cash And Equivalents = 518.4m CHF (last quarter)
P/E Trailing = 31.5494
P/S = 6.925
P/B = 7.8901
Beta = 0.691
Revenue TTM = 4.26b CHF
EBIT TTM = 1.04b CHF
EBITDA TTM = 1.15b CHF
Long Term Debt = 29.0k CHF (from longTermDebt, last quarter)
Short Term Debt = 3.44m CHF (from shortTermDebt, last quarter)
Debt = 3.46m CHF (Calculated: Short Term 3.44m + Long Term 29.0k)
Net Debt = -509.6m CHF (from netDebt column, last quarter)
Enterprise Value = 13.96b CHF (14.48b + Debt 3.46m - CCE 518.4m)
Interest Coverage Ratio = 266.9 (Ebit TTM 1.04b / Interest Expense TTM 3.91m)
FCF Yield = 7.39% (FCF TTM 1.03b / Enterprise Value 13.96b)
FCF Margin = 24.21% (FCF TTM 1.03b / Revenue TTM 4.26b)
Net Margin = 21.56% (Net Income TTM 918.4m / Revenue TTM 4.26b)
Gross Margin = 45.38% ((Revenue TTM 4.26b - Cost of Revenue TTM 2.33b) / Revenue TTM)
Tobins Q-Ratio = 6.96 (Enterprise Value 13.96b / Book Value Of Equity 2.01b)
Interest Expense / Debt = 2.83% (Interest Expense 98.0k / Debt 3.46m)
Taxrate = 15.10% (from yearly Income Tax Expense: 82.9m / 549.0m)
NOPAT = 885.4m (EBIT 1.04b * (1 - 15.10%))
Current Ratio = 6.06 (Total Current Assets 1.46b / Total Current Liabilities 240.8m)
Debt / Equity = 0.00 (Debt 3.46m / last Quarter total Stockholder Equity 1.83b)
Debt / EBITDA = 0.00 (Net Debt -509.6m / EBITDA 1.15b)
Debt / FCF = 0.00 (Debt 3.46m / FCF TTM 1.03b)
Total Stockholder Equity = 1.90b (last 4 quarters mean)
RoA = 41.23% (Net Income 918.4m, Total Assets 2.23b )
RoE = 48.30% (Net Income TTM 918.4m / Total Stockholder Equity 1.90b)
RoCE = 54.84% (Ebit 1.04b / (Equity 1.90b + L.T.Debt 29.0k))
RoIC = 46.43% (NOPAT 885.4m / Invested Capital 1.91b)
WACC = 7.16% (E(14.48b)/V(14.48b) * Re(7.16%)) + (D(3.46m)/V(14.48b) * Rd(2.83%) * (1-Tc(0.15)))
Shares Correlation 5-Years: 0.0 | Cagr: 0.0%
Discount Rate = 7.16% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 80.97% ; FCFE base≈917.2m ; Y1≈1.09b ; Y5≈1.73b
Fair Price DCF = 1264 (DCF Value 29.55b / Shares Outstanding 23.4m; 5y FCF grow 20.58% → 3.0% )
Revenue Correlation: -56.22 | Revenue CAGR: -5.98%
Rev Growth-of-Growth: -24.95
EPS Correlation: -13.18 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -222.5